RayKnowChina Research Map
Shortlist0

Enrolling by invitationStomach cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Qilu Hospital of Shandong University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07488312, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed gastric carcinoma requiring preoperative endoscopic localization marking or delineation of the lesion extent.

    Inclusion criterion 1

  3. Postoperative pathological diagnosis confirming non-primary gastric cancer.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07488312, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Pathologically confirmed gastric carcinoma requiring preoperative endoscopic localization marking or delineation of the lesion extent.
  • Aged between 18 and 70 years, regardless of gender.
  • Ability to consume oral or nasogastric tube feeding of a liquid diet.
  • Provision of signed informed consent and voluntary participation in this study.
  • No evidence of distant metastasis on preoperative imaging studies (e.g., CT, PET-CT), and deemed suitable for surgical resection.
  • No concurrent diagnosis of other active malignancies.

Exclusion Criteria:

  • Presence of cognitive impairment or psychological disorders that may compromise the understanding of the research content.
  • Diagnosis of Type I or Type II Diabetes Mellitus.
  • Severe diarrhea, intractable vomiting, severe malabsorption syndromes, paralytic or mechanical intestinal obstruction, or active gastrointestinal bleeding.
  • Known allergy to the primary components of the leucine-deficient nutritional formula.
  • Concurrent use of other nutritional supplements that may interfere with the trial's efficacy.
  • Postoperative pathological diagnosis confirming non-primary gastric cancer.

Quoted from ClinicalTrials.gov, NCT07488312, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07488312, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07488312